Findings

What do systematic reviews say?

9 questions · 9 findings · 1 reviews · Colorectal

No studies found 2 · 22.2%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 33.3%Moderate 4 · 44.4%High 0 · 0%

Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ KRAS exon 2 MT

The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 32.35 [15.01, 69.7]
5 studies · 1635 participants
Moderate

Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS WT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS MT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1341 participants
Low

Grade 3 to 4 rash · people with metastatic colorectal cancer

The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 47.53 [14.84, 152.19]
3 studies · 1951 participants
Moderate

Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1651 participants
Low

Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ KRAS exon 2 WT

The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 23.42 [13.22, 41.49]
7 studies · 2909 participants
Moderate

Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 99 participants
Low

Grade 3 to 4 rash · people with metastatic colorectal cancer

The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 67.52 [30.83, 147.85]
4 studies · 2363 participants
Moderate